Renovorx Inc stock is traded at $1.19, with a volume of 357,606. It is down -9.16% in the last 24 hours and down -14.39% over the past month. RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Previous Close:
$1.31
Open:
$1.30
24h Volume:
357,606
Relative Volume:
1.26
Market Cap:
$53.70M
Revenue:
$1.49M
Net Income/Loss:
-$12.27M
P/E Ratio:
-
EPS:
-$0.3316
Net Cash Flow:
-$11.30M
1W Performance:
-10.53%
1M Performance:
-14.39%
6M Performance:
+33.72%
1Y Performance:
+23.21%
1-Day Range:
$0.00$0.00
1-Week Range:
$1.13$1.37
52-Week Range:
$0.7006$2.59
Renovorx Inc Stock (RNXT) Company Profile
Name
Renovorx IncSector
HealthcareIndustry
BiotechnologyPhone
408-800-2649Address
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS